Skip to main content

Accelrys Revenues Slide, Losses Widen in Q1 of FY05

NEW YORK, July 30 (GenomeWeb News) - Accelrys yesterday reported a sharp drop in revenues and a widening loss for the first quarter of its fiscal year 2005, ended June 30.


The company had $14.2 million in revenues, down from $19.1 million during the same quarter last year. Accelrys attributed this drop in part to a change in revenue recognition for annual and multi-year licenses and smaller consulting and consortia revenues. The change in revenue recognition "will continue to dramatically affect reported revenue through the next three to four quarters," according to a company statement.


Research and development costs stayed flat, at $4.1 million, compared to $4.6 million during the same quarter a year ago.


The net loss for the quarter totaled $6.2 million, or $.25 per share, up from $3.8 million, or $.16 per share, during the year-ago quarter. This included a $1.1 million loss from the discontinued Pharmacopeia Drug Discovery unit.


As of June 30, Accelrys, which changed its name from Pharmacopeia in May, had $83.8 million in cash, restricted cash, cash equivalents, and marketable securities.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.